FindTrial
Sign In

Ipilimumab (YervoyTM, 50 mg/10 mL solution)

DRUG3 trials

Sponsors

Universitair Ziekenhuis Brussel, BioInvent International AB, UNICANCER

Conditions

Cutaneous Melanoma, Stage IIIGlioblastomaMelanomaMelanoma BRAF V600E/K MutatedMelanoma MetastaticMelanoma Negative for bRAFMelanoma Negative for nRASMelanoma Recurrent

Phase 1

A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.
Active, not recruitingNCT03233152
Universitair Ziekenhuis BrusselGlioblastoma
Start: 2016-11-17End: 2026-11-17Updated: 2025-11-21
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Active, not recruitingNCT06784648
BioInvent International ABMelanoma, Melanoma BRAF V600E/K Mutated, Melanoma Metastatic +7
Start: 2024-12-11End: 2025-12-30Target: 35Updated: 2025-11-19

Phase 2

Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
RecruitingNCT07230613
UNICANCERCutaneous Melanoma, Stage III, Mucosal Melanoma
Start: 2026-01-12End: 2033-12-01Target: 50Updated: 2026-07-21

Related Papers

Immunohistochemical and gene expression profiles as predictors of survival in recurrent high-grade glioma treated with intracranial nivolumab, ipilimumab, and autologous CD1c(BDCA-1) <sup>+</sup> /CD141(BDCA-3) <sup>+</sup> myeloid dendritic cells (myDC).
Journal of Clinical Oncology2025-05-28
Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma
Neuro-Oncology2024-10-1620 citations
OS03.5.A A PHASE I CLINICAL TRIAL ON THE INTRACRANIAL ADMINISTRATION OF AUTOLOGOUS CD1C(BDCA-1)+ /CD141(BDCA-3)+ MYELOID DENDRITIC CELLS IN COMBINATION WITH IPILIMUMAB AND NIVOLUMAB IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA
Neuro-Oncology2024-10-01
A phase I trial on the intra- and post-operative intracranial administration of ipilimumab and nivolumab in patients with recurrent high-grade glioma.
Journal of Clinical Oncology2024-06-01
494 Evaluating ERK1 2 Phosphorylation as a Predictive Biomarker for Survival in Recurrent Glioblastoma Patients: A REMARK Criteria-guided Analysis of a Clinical Trial Cohort Treated With Intracerebral PD-1 and CTLA-4 Blockade
Neurosurgery2024-03-15
ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis.
2024-01-019 citations
BIOM-39. P-ERK ASSOCIATION WITH OVERALL SURVIVAL IN RECURRENT GBM PATIENTS TREATED WITH INTRACEREBRAL ADMINISTRATION OF PD-1 AND CTLA-4 BLOCKING ANTIBODIES
Neuro-Oncology2022-11-01
CTIM-12. A PHASE I CLINICAL TRIAL ON THE INTRACRANIAL ADMINISTRATION OF INCREASING DOSES OF IPILIMUMAB PLUS FIXED DOSE NIVOLUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGB)
Neuro-Oncology2022-11-01
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Journal of Clinical Oncology2022-06-011 citations
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial
Journal for ImmunoTherapy of Cancer2021-06-01100 citations
A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma.
Journal of Clinical Oncology2020-05-2011 citations